7 recruiting, 6 unknown, 3 active not recruiting, 2 completed. 19 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Recruiting 7, Unknown 6, Active not recruiting 3, Completed 2, Terminated 1 |
| Phase 2 | 9 | Recruiting 5, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow Melanoma Stage IV: new trials by email Literature Review of Melanoma Stage IV trials Research Report on Melanoma Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2025-04-01 | 2025-08-24 |
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-04-07 |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors GIM-531, Anti-PD-1 monoclonal antibody - Melanoma Stage IV, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 117 | 2024-05-09 | 2026-08-14 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| Intrathecal Double Checkpoint Inhibition intrathecal nivolumab and intrathecal ipilimumab - Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV | Phase 1 | Active not recruiting | University of Zurich | 26 | 2022-11-25 | 2025-10-02 |
| FMT to Convert Response to Immunotherapy Fecal microbiota transplantation - Melanoma Stage III, Melanoma Stage IV | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 24 | 2022-08-31 | 2025-03-10 |
| Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI - NSCLC Stage IV, Melanoma Stage IV | Phase 1 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 45 | 2022-06-29 | 2025-07-30 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT - Sarcoma, Synovial, Sarcoma,Soft Tissue | Phase 1 / Phase 2 | Recruiting | Hadassah Medical Organization | 3 | 2022-04-01 | 2025-10-02 |
| Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), Recombinant humanized anti-PD-1 monoclonal antibody for injection, Axitinib - Melanoma Stage IV | Phase 1 | Unknown | Peking University Cancer Hospital & Institute | 30 | 2021-10-01 | 2021-10-07 |
| Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF), Recombinant humanized anti-PD-1 monoclonal antibody for injection, RT - Melanoma Stage IV | Phase 1 | Unknown | Peking University Cancer Hospital & Institute | 15 | 2021-10-01 | 2021-10-05 |
| Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients TRIMELVAX - Melanoma Stage IIIc, Melanoma Stage IV | Phase 1 | Unknown | University of Chile | 20 | 2021-05-02 | 2024-08-15 |
| Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy [203Pb]VMT01, [68Ga]VMT02 - Melanoma (Skin), Melanoma Stage IV | Phase 1 | Completed | Perspective Therapeutics | 7 | 2021-03-05 | 2023-11-07 |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC Fecal Microbial Transplantation by capsules - Melanoma Stage IV, Unresectable Melanoma | Phase 1 / Phase 2 | Unknown | Ella Therapeutics Ltd | 42 | 2020-11-01 | 2021-08-16 |
| Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 EVX-02A, EVX-02B, EVX-02A OR EVX-02B - Melanoma Stage IV, Melanoma Stage III | Phase 1 / Phase 2 | Terminated | Evaxion Biotech A/S | 15 | 2020-07-13 | 2024-02-21 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors ST101, Temozolomide, Radiation - Glioblastoma, Melanoma Stage IV | Phase 1 / Phase 2 | Active not recruiting | Sapience Therapeutics | 125 | 2020-07-01 | 2026-02-09 |
| SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab SX-682, Pembrolizumab - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Active not recruiting | Syntrix Biosystems, Inc. | 77 | 2019-06-12 | 2025-12-23 |
| Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma Denosumab, Nivolumab, Ipilimumab - Melanoma Stage Iv, Melanoma Stage Iii | Phase 1 / Phase 2 | Unknown | Melanoma and Skin Cancer Trials Limited | 72 | 2017-12-07 | 2022-04-07 |
| Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy Fecal Microbiota Transplant (FMT) - Melanoma Stage Iv, Unresectable Stage III Melanoma | Phase 1 | Unknown | Sheba Medical Center | 40 | 2017-11-30 | 2019-04-03 |
Melanoma (19) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (2) · Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Disease (1) · Glioblastoma (1) · Kidney Neoplasms (1) · Meningeal Carcinomatosis (1) · Mesothelioma (1) · Neuroblastoma (1) · Ovarian Neoplasms (1)
Neoplasms by Histologic Type (19) · Neoplasms by Site (19) · Neoplasms, Germ Cell and Embryonal (19) · Neoplasms, Nerve Tissue (19) · Neuroectodermal Tumors (19) · Neuroendocrine Tumors (19) · Nevi and Melanomas (19) · Skin Diseases (19) · Skin Neoplasms (19) · Skin and Connective Tissue Diseases (19) · Neoplasms (17) · Bronchial Neoplasms (5) · Carcinoma, Bronchogenic (5) · Lung Diseases (5) · Lung Neoplasms (5)
Nivolumab (3) · Cyclophosphamide (2) · Fecal Microbiota Transplantation (2) · Injections (2) · aldesleukin (2) · Axitinib (1) · Denosumab (1) · Interleukin-2 (1) · Ipilimumab (1) · Opdualag (1) · Radiation (1) · Temozolomide (1) · atezolizumab (1) · fludarabine phosphate (1) · pembrolizumab (1)
Peking University Cancer Hospital & Institute (2) · Perspective Therapeutics (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Ella Therapeutics Ltd (1) · Evaxion Biotech A/S (1) · Georgiamune Inc (1) · Hadassah Medical Organization (1) · Inge Marie Svane (1) · KaliVir Immunotherapeutics (1) · Krystal Biotech, Inc. (1) · Melanoma and Skin Cancer Trials Limited (1) · Sapience Therapeutics (1) · Sheba Medical Center (1) · Syntrix Biosystems, Inc. (1) · The Netherlands Cancer Institute (1)
United States (7) · Israel (3) · Australia (2) · Canada (1) · Chile (1) · Denmark (1) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
Abi Vainstein-Haras, MD (1) · Arielle Elkrief, MD (1) · Cecilie D Vestergaard, M.D. (1) · David Chien, MD (1) · Dr Bavanthi Balakrishnar (1) · Flavio Salazar, PhD (1) · Frances L Johnson, MD (1) · Gal Markel, MD, PhD (1) · Geoffrey B Johnson, MD, PhD (1) · Guy Ben-Betzalel, MD (1) · Inge Marie Svane, Prof., M.D. (1) · John Haanen, Prof (1) · Michal Lotem, MD (1) · Prof. Grant McArthur (1)
PMID 36464584, PMID 36585700, PMID 37754485, PMID 42062531
R44CA217591 (1)